Background Severe asthma is a major cause of morbidity. Some patients may benefit from
biological therapies. Most evaluations of these treatments are derived from randomized …

Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal
antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing …

Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine implicated in the
initiation and persistence of inflammatory pathways in asthma. Released in response to a …

Severe asthma often remains uncontrolled despite effective treatments and evidence-based
guidelines. A group of global experts in asthma and biologic medications from 9 countries …

Asthma is a disease with high incidence and prevalence, and its severe form accounts for
approximately 10% of asthmatics. Over the last decade, the increasing knowledge of the …

Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin, an
epithelial-cell-derived cytokine implicated in the pathogenesis of asthma. It was approved by …

Background Many severe asthma patients with high oral corticosteroid exposure (HOCS)
often do not initiate biologics despite being eligible. This study aimed to compare the …

Background Whilst multidimensional assessment enables the detection of treatable traits in
severe asthma and has the potential to improve patient outcomes, healthcare disparities …

The prevalence and incidence of asthma are increasing globally because of genetic and
environmental influences. Prevalence of asthma in the Gulf has been reported to range from …

Background Although there have been indirect comparisons of the relative efficacy of
mepolizumab (anti-IL-5) and benralizumab (anti-IL-5Rα) in severe asthma patients, long …